CD274 and neoplasm: Post-immunotherapy scenarios where there is no appreciable increase in T effector cells coupled with a decrease in Tregs, or a surge in Treg cells within the tumor matrix, are often indicative of resistance to PD-1/PD-L1 monoclonal antibody therapies.